



June 16, 2016

AnGes MG, Inc.

**AnGes Announces a Basic Agreement with Morishita Jintan for the Exclusive Development, Manufacturing, and Marketing Rights of CIN Therapeutic Vaccine**

AnGes MG, Inc. (“AnGes”) announced that it has concluded a basic agreement with Morishita Jintan Co., Ltd. (Head office: Chuo-ku, Osaka, President & CEO: Junichi Komamura, “Morishita Jintan”) to license out the exclusive development, manufacturing, and marketing rights of its CIN Therapeutic Vaccine to Morishita Jintan.

CIN Therapeutic Vaccine is an innovative orally administered vaccine that prevents cervical intraepithelial neoplasia (CIN) from progressing to cervical cancer. AnGes acquired the exclusive rights in Japan, the US, China and UK from BioLeaders Corporation, a South Korean biotech company. AnGes developed the CIN Therapeutic Vaccine in collaboration with Dr. Kei Kawana (Obstetrics & Gynecology, the University of Tokyo Hospital). The Dr. Kawana’s research group is currently conducting a physician-led clinical study at the University of Tokyo Hospital.

Under the terms of this basic agreement, AnGes will license out all of its rights related to CIN Therapeutic Vaccine to Morishita Jintan. AnGes will receive an upfront payment and will also be eligible to receive sales-based royalties. A definitive agreement is to be concluded after the two companies reach an agreement on the details.

AnGes intends to maximize its rights for CIN Therapeutic Vaccine through the royalties it receives in the future once the product is successfully launched on the market. At the same time, moving forward it will focus on the development of its core projects for gene therapy and nucleic-acid drugs.

AnGes will receive an upfront payment following the conclusion of a definitive agreement. This event may have an impact on the financial performance for the fiscal period ending December 31, 2016. AnGes will make an announcement if it becomes necessary to amend the business performance forecast that was announced on February 5, 2016.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

AnGesMG, Inc.  
Corporate Communications  
TEL:+81-3-5730-2641, FAX:+81-3-5730-2635  
<http://www.anges-mg.com>